☆ 4.7 Meeting Abstract

TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants

EUROPEAN JOURNAL OF CANCER (2016)

Get Full Text
Add to Collection

Journal

EUROPEAN JOURNAL OF CANCER
Volume 69, Issue -, Pages S32-S32

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/S0959-8049(16)32675-2

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.